Skip to main content

BAX

Stock
Health Care
Medical Instruments & Supplies

Performance overview

BAX Price
Price Chart

Forward-looking statistics

Beta
0.63
Risk
29.03%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.

Company info

SectorHealth Care
IndustryMedical Instruments & Supplies
Employees46K
Market cap$16.9B

Fundamentals

Enterprise value$23.5B
Revenue$10.8B
Revenue per employee
Profit margin-5.20%
Debt to equity146.14

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)-$0.52
Dividend per share$0.68
Revenue per share$21.08
Avg trading volume (30 day)$96M
Avg trading volume (10 day)$98M
Put-call ratio

Macro factor sensitivity

Growth+1.0
Credit+1.3
Liquidity-0.7
Inflation-0.9
Commodities+1.0
Interest Rates-0.0

Valuation

Dividend yield2.19%
PEG Ratio10.77
Price to sales1.48
P/E Ratio10.77
Enterprise Value to Revenue2.18
Price to book2.25

Upcoming events

Next earnings dayMay 1, 2025
Next dividend day
Ex. dividend dayMay 30, 2025

News

BAX Stock May Rise Following the Launch of FDA-Approved Hemopatch Pad

Baxter launches Hemopatch Sealing Hemostat, an FDA-approved collagen pad designed for effective hemostasis and sealing in both open and minimally invasive surgeries.

Zacks Investment Research (May 21, 2025)
Baxter Reports Strong Medical Devices Sales In Q1, Lifts 2025 Guidance, Stock Jumps

On Thursday, Baxter International Inc. BAX reported a first-quarter 2025 adjusted EPS of 62 cents, beating the management guidance of 47 to 50 cents and the Wall Street estimate of 48 cents.

Benzinga (May 1, 2025)
Goldman's John Marshall provides stock opportunities ahead of earning season

John Marshall, Goldman Sachs head of derivatives research, joins 'Money Movers' to discuss the current market environment, individual companies Goldman looked at, and much more.

CNBC Television (April 17, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free